BRPI0414008A - peptìdeos e compostos que se ligam a um receptor - Google Patents

peptìdeos e compostos que se ligam a um receptor

Info

Publication number
BRPI0414008A
BRPI0414008A BRPI0414008-7A BRPI0414008A BRPI0414008A BR PI0414008 A BRPI0414008 A BR PI0414008A BR PI0414008 A BRPI0414008 A BR PI0414008A BR PI0414008 A BRPI0414008 A BR PI0414008A
Authority
BR
Brazil
Prior art keywords
peptides
compounds
bind
receptor
tpo
Prior art date
Application number
BRPI0414008-7A
Other languages
English (en)
Inventor
Brian R Macdonald
Jeffrey Kenneth Weis
Edward John Yurkow
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BRPI0414008A publication Critical patent/BRPI0414008A/pt
Publication of BRPI0414008B1 publication Critical patent/BRPI0414008B1/pt
Publication of BRPI0414008B8 publication Critical patent/BRPI0414008B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PEPTìDEOS E COMPOSTOS QUE SE LIGAM A UM RECEPTOR". A presente invenção refere-se a peptídeos e compostos que se ligam a e ativam o receptor de trombopoietina (c-mpl ou TPO-R) ou, de outro modo, atuam como um agonista de TPO que são descritos.
BRPI0414008A 2003-08-28 2004-08-13 compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula BRPI0414008B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
US60/498,740 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (3)

Publication Number Publication Date
BRPI0414008A true BRPI0414008A (pt) 2006-10-24
BRPI0414008B1 BRPI0414008B1 (pt) 2018-05-15
BRPI0414008B8 BRPI0414008B8 (pt) 2021-05-25

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414008A BRPI0414008B8 (pt) 2003-08-28 2004-08-13 compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula

Country Status (32)

Country Link
US (1) US7576056B2 (pt)
EP (1) EP1675606B1 (pt)
JP (1) JP4848277B2 (pt)
KR (2) KR20120078742A (pt)
CN (2) CN1871022B (pt)
AR (1) AR045530A1 (pt)
AU (1) AU2004270656B2 (pt)
BR (1) BRPI0414008B8 (pt)
CA (1) CA2537421C (pt)
CY (1) CY1118965T1 (pt)
DK (1) DK1675606T3 (pt)
EA (1) EA009286B1 (pt)
EC (1) ECSP066396A (pt)
ES (1) ES2626107T3 (pt)
HR (1) HRP20170810T1 (pt)
HU (1) HUE032370T2 (pt)
IL (1) IL173965A (pt)
IS (1) IS8300A (pt)
LT (1) LT1675606T (pt)
ME (1) ME00313B (pt)
MX (1) MXPA06002292A (pt)
NO (1) NO344233B1 (pt)
NZ (1) NZ545455A (pt)
PL (1) PL1675606T3 (pt)
PT (1) PT1675606T (pt)
RS (2) RS20060141A (pt)
SG (1) SG131110A1 (pt)
SI (1) SI1675606T1 (pt)
TW (1) TWI348375B (pt)
UA (1) UA82710C2 (pt)
WO (1) WO2005023834A2 (pt)
ZA (1) ZA200602495B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
DK1542714T3 (da) * 2002-09-18 2014-05-26 Janssen Pharmaceuticals Inc Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
RS20060141A (sr) 2003-08-28 2008-08-07 Ortho-Mcneil Pharmaceutical Inc., Peptidi i jedinjenja koja se vežu za receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
AR059573A1 (es) * 2006-02-14 2008-04-16 Janssen Pharmaceutica Nv Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia
PT1984014E (pt) * 2006-02-14 2014-11-13 Janssen Pharmaceutica Nv Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
KR20110015448A (ko) * 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드
CN103635514B (zh) 2011-06-23 2016-01-20 株式会社岛津制作所 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送系统
JP7481252B2 (ja) * 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ．ベー． 標的放射線治療誘発性血管完全性を保護する方法
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
US11273203B2 (en) 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
CN118660955A (zh) 2021-10-01 2024-09-17 詹森药业有限公司 增加祖细胞生产的方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
EP0945504A3 (en) * 1992-12-11 1999-12-08 The University Of Florida Materials and method for control of pests
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021920A1 (en) 1994-02-14 1995-08-17 Zymogenetics, Inc. Hematopoietic protein and materials and methods for making it
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EE9600121A (et) 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
CA2180021A1 (en) * 1994-11-04 1996-05-17 Yoichi Kawashima Novel 1,3-dialkylurea derivatives having a hydroxyl group
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
WO1996034016A1 (en) 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptides
CN1966520B (zh) * 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
ES2266104T3 (es) * 2000-12-22 2007-03-01 Ipsen Manufacturing Ireland Limited Procedimiento para la sintesis de un peptido lhrh.
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
DK1542714T3 (da) * 2002-09-18 2014-05-26 Janssen Pharmaceuticals Inc Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
RS20060141A (sr) 2003-08-28 2008-08-07 Ortho-Mcneil Pharmaceutical Inc., Peptidi i jedinjenja koja se vežu za receptor

Also Published As

Publication number Publication date
SI1675606T1 (sl) 2017-07-31
EA009286B1 (ru) 2007-12-28
MEP48508A (en) 2011-02-10
HUE032370T2 (en) 2017-09-28
WO2005023834A2 (en) 2005-03-17
TW200517103A (en) 2005-06-01
CA2537421C (en) 2011-09-27
RS56387B1 (sr) 2017-12-29
CN1871022B (zh) 2011-07-06
SG131110A1 (en) 2007-04-26
CY1118965T1 (el) 2018-01-10
AR045530A1 (es) 2005-11-02
NZ545455A (en) 2009-02-28
IL173965A (en) 2015-10-29
RS20060141A (sr) 2008-08-07
CN102241742A (zh) 2011-11-16
TWI348375B (en) 2011-09-11
KR101183875B1 (ko) 2012-09-27
BRPI0414008B8 (pt) 2021-05-25
EA200600477A1 (ru) 2007-02-27
PT1675606T (pt) 2017-05-22
LT1675606T (lt) 2017-11-10
PL1675606T3 (pl) 2017-08-31
BRPI0414008B1 (pt) 2018-05-15
WO2005023834A3 (en) 2005-05-06
NO344233B1 (no) 2019-10-14
AU2004270656A1 (en) 2005-03-17
IS8300A (is) 2006-02-14
NO20061346L (no) 2006-05-22
EP1675606B1 (en) 2017-04-05
ZA200602495B (en) 2007-06-27
CA2537421A1 (en) 2005-03-17
HRP20170810T1 (hr) 2017-08-11
JP2007504132A (ja) 2007-03-01
EP1675606A2 (en) 2006-07-05
MXPA06002292A (es) 2006-09-04
CN102241742B (zh) 2014-04-02
UA82710C2 (uk) 2008-05-12
IL173965A0 (en) 2006-07-05
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
KR20070017942A (ko) 2007-02-13
US7576056B2 (en) 2009-08-18
ES2626107T3 (es) 2017-07-24
KR20120078742A (ko) 2012-07-10
US20050137133A1 (en) 2005-06-23
ECSP066396A (es) 2006-08-30
AU2004270656B2 (en) 2011-03-10
HK1096873A1 (en) 2007-06-15
CN1871022A (zh) 2006-11-29
ME00313B (me) 2011-05-10
JP4848277B2 (ja) 2011-12-28

Similar Documents

Publication Publication Date Title
CY1118965T1 (el) Πεπτιδια και ενωσεις που συνδεονται με ενα υποδοχεα
NI200800040A (es) Péptidos y compuestos que se unen a un receptor
ECSP034600A (es) Compuestos de lactama
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
BRPI0511008A (pt) agentes de ligação de il-13
BRPI0605921A2 (pt) compostos orgánicos
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
WO2007140505A3 (en) Vaccine carrier
DK1520897T3 (da) Adhæsive strukturer til fastgörelse til hud
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE50308324D1 (de) 2-phenyl-2-substituirte-1, 3-diketone als schädlingsbekämpfungsmittel
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
BR0302743B1 (pt) conjunto de travamento de unidade de plantio.
WO2008036337A8 (en) Predicted phosphorylation sites
DE60319989D1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
WO2008030543A3 (en) Tyrosine, serine and threonine phosphorylation sites
WO2007039606A3 (en) Insulin receptor antagonists and related compositions, uses and methods
WO2007072022A3 (en) Composition comprising an antigen-recognizing molecule and a lipid-based carrier
汤韬 Open Source
TW200730104A (en) Locking device
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.